世界のファーマコゲノミクス技術市場(2023-2030):治療領域別、技術別(PCR、インサイチュハイブリダイゼーション、免疫組織化学、シークエンシング、その他)、地域別

【英語タイトル】Pharmacogenomics Technology Market Size, Share & Trends Analysis Report By Therapeutic Area, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料(GRV23NOV180)・商品コード:GRV23NOV180
・発行会社(調査会社):Grand View Research
・発行日:2023年9月
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:臨床診断
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,360,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

ファーマコゲノミクス技術市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界のファーマコゲノミクス技術市場規模は、2023年から2030年にかけて年平均成長率8.7%で拡大し、2030年には123億米ドルに達する見込みです。診断学は、新たな生物学的療法の導入に続く薬理ゲノム検査の波に対応しつつあります。これらの検査は費用対効果の高い治療を可能にし、医薬品開発のプロセスにも付加価値を与えます。疾患リスク予測、患者層別化、治療反応モニタリングなど、これらの検査の使用に関連する利点は、従来の方法に比べて、このファーマコゲノミクスコンパニオン診断市場の重要な進歩の源になると予想されます。

さらに、ファーマコゲノミクス検査製品は、患者の治療レジメンの個別化と最適化において医師を支援します。ファーマコゲノミクスとセラノスティクスは統合医療への道を開きます。この特殊な分子診断検査群の急速な進化は、疾患のリアルタイム治療評価の改善に寄与しています。

しかし、ファーマコゲノミクスに基づく検査を医薬品開発のタイムラインに早期に組み込んで同時に承認を得ることに関連する課題が存在することが、成長の妨げになると予想されます。与えられた治療による個人差や集団差を特定するための臨床試験の適切な設計と実施は、セラノスティクスの成功に必要な属性となっています。

ファーマコゲノミクス技術市場レポートハイライト

- このセグメントには多数の製品が存在するため、がん領域が最大の売上シェアを占めると推定されます。

- さらに、精密腫瘍学の研究者は、腫瘍の成長を抑えるだけでなく、腫瘍を縮小させるために、様々な種類の組み合わせで複数の薬剤を投与することを想定しています。

- 前述の事実が、ファーマコゲノミクス技術市場における癌の推定売上シェアの原因となっています。

- ポリメラーゼ連鎖反応(PCR)は、セラノスティクスの技術に関して最大の収益を上げるセグメントでした。

- PCR技術の使用に伴う利点により、PCRは現在臨床診断の主力技術となっています。

- さらに、感度を犠牲にすることなくアッセイで得られる再現性のある正確な結果が、推定シェアの原因となっています。

- 北米地域がファーマコゲノミクス技術市場を支配しています。

- アジア太平洋地域は、企業が未開拓のビジネスチャンスの獲得に取り組んでいることから、予測期間中に最も速い成長を示すと予測されています。

- 主な参入企業は、F Hoffman La Roche、Agilent Technologies、Thermo Fisher Scientific Inc.、GE Healthcare、Pfizer、Qiagen NV、Leica Biosystems Nussloch GmBH、Foundation Medicineなどがあります。

- 診断薬企業は、体外診断技術の応用範囲を拡大することにより、疾病の検出だけでなく、セラノスティックツールを提供することを位置づけています。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. 世界のファーマコゲノミクス技術市場:治療領域別予測・動向分析
第5章. 世界のファーマコゲノミクス技術市場:技術別予測・動向分析
第6章. 世界のファーマコゲノミクス技術市場:地域別予測・動向分析
第7章. 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Therapeutic area
1.1.2. Technology
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapeutic area outlook
2.2.2. Technology outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Pharmacogenomics Technology Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Pharmacogenomics Technology Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis
4.1. Pharmacogenomics Technology Market: Key Takeaways
4.2. Pharmacogenomics Technology Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Oncology
4.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.1.1. Lung cancer
4.3.1.1.1. Lung cancer market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.2. Breast cancer
4.3.1.2.1. Breast cancer market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.3. Colorectal cancer
4.3.1.3.1. Colorectal cancer market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.4. Cervical cancer
4.3.1.4.1. Cervical cancer market estimates and forecast 2018 to 2030 (USD Million)
4.3.1.5. Others
4.3.1.5.1. Others cancer market estimates and forecast 2018 to 2030 (USD Million)
4.4. Neurological Disorders
4.4.1. Neurological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Cardiovascular Disease
4.5.1. Cardiovascular disease market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Immunological Disorders
4.6.1. Immunological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Infectious Disease
4.7.1. Infectious disease market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Pharmacogenomics Technology: Technology Estimates & Trend Analysis
5.1. Pharmacogenomics Technology Market: Key Takeaways
5.2. Pharmacogenomics Technology Market: Movement & Market Share Analysis, 2022 & 2030
5.3. PCR
5.3.1. PCR market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. In-situ Hybridization
5.4.1. In-situ hybridization market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Immunohistochemistry
5.5.1. Immunohistochemistry market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Sequencing
5.6.1. Sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Pharmacogenomics Technology Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Pharmacogenomics Technology Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. QIAGEN
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. GE HealthCare
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Agilent Technologies, Inc.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. F. Hoffmann-La Roche Ltd.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. FOUNDATION MEDICINE, INC.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Thermo Fisher Scientific Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Leica Biosystems Nussloch GmBH
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Pfizer Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviations
Table 2 North America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 3 North America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 4 North America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 6 U.S. pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 7 Canada pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 8 Canada pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 9 Europe pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 10 Europe pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 11 Europe pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 12 Germany pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 13 Germany pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 14 UK pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 15 UK pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 16 France pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 17 France pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 18 Italy pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 19 Italy pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 20 Spain pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 21 Spain pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 22 Sweden pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 23 Sweden pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 24 Norway pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 25 Norway pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 26 Denmark pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 27 Denmark pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 28 Asia Pacific pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 29 Asia Pacific pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 30 Asia Pacific pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 31 China pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 32 China pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 33 Japan pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 34 Japan pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 35 India pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 36 India pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 37 Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 38 Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 39 Thailand pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 40 Thailand pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 41 South Korea pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 42 South Korea pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 43 Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 44 Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 45 Latin America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 46 Latin America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 47 Latin America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 48 Brazil pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 49 Brazil pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 50 Mexico pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 51 Mexico pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 52 Argentina pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 53 Argentina pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 55 Middle East and Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 56 Middle East and Africa pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 57 South Africa pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 58 South Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 61 UAE pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 62 UAE pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 63 Kuwait pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 64 Kuwait pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Pharmacogenomics technology: Market outlook
Fig. 9 Pharmacogenomics technology: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Pharmacogenomics technology market driver impact
Fig. 15 Pharmacogenomics technology market restraint impact
Fig. 16 Pharmacogenomics technology market strategic initiatives analysis
Fig. 17 Pharmacogenomics technology market: Therapeutic area movement analysis
Fig. 18 Pharmacogenomics technology market: Therapeutic area outlook and key takeaways
Fig. 19 Oncology market estimates and forecasts, 2018 - 2030
Fig. 20 Neurological disorders market estimates and forecasts, 2018 - 2030
Fig. 21 Cardiovascular diseases market estimates and forecasts, 2018 - 2030
Fig. 22 Immunological disorders market estimates and forecasts, 2018 - 2030
Fig. 23 Infectious diseases market estimates and forecasts, 2018 - 2030
Fig. 24 Others market estimates and forecasts, 2018 - 2030
Fig. 25 Pharmacogenomics technology market: Technology movement analysis
Fig. 26 Pharmacogenomics technology market: Technology outlook and key takeaways
Fig. 27 PCR market estimates and forecasts, 2018 - 2030
Fig. 28 In-situ hybridization delivery market estimates and forecasts, 2018 - 2030
Fig. 29 Immunohistochemistry market estimates and forecasts, 2018 - 2030
Fig. 30 Sequencing market estimates and forecasts, 2018 - 2030
Fig. 31 Others market estimates and forecasts, 2018 - 2030
Fig. 32 Global Pharmacogenomics technology market: Regional movement analysis
Fig. 33 Global Pharmacogenomics technology market: Regional outlook and key takeaways
Fig. 34 North America market estimates and forecasts, 2018 - 2030
Fig. 35 U.S. market estimates and forecasts, 2018 - 2030
Fig. 36 Canada market estimates and forecasts, 2018 - 2030
Fig. 37 Europe. market estimates and forecasts, 2018 - 2030
Fig. 38 UK market estimates and forecasts, 2018 - 2030
Fig. 39 Germany market estimates and forecasts, 2018 - 2030
Fig. 40 France market estimates and forecasts, 2018 - 2030
Fig. 41 Italy market estimates and forecasts, 2018 - 2030
Fig. 42 Spain market estimates and forecasts, 2018 - 2030
Fig. 43 Sweden market estimates and forecasts, 2018 - 2030
Fig. 44 Norway market estimates and forecasts, 2018 - 2030
Fig. 45 Denmark market estimates and forecasts, 2018 - 2030
Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 47 Japan market estimates and forecasts, 2018 - 2030
Fig. 48 China market estimates and forecasts, 2018 - 2030
Fig. 49 India market estimates and forecasts, 2018 - 2030
Fig. 50 Australia market estimates and forecasts, 2018 - 2030
Fig. 51 Thailand market estimates and forecasts, 2018 - 2030
Fig. 52 South Korea market estimates and forecasts, 2018 - 2030
Fig. 53 Latin America market estimates and forecasts, 2018 - 2030
Fig. 54 Brazil market estimates and forecasts, 2018 - 2030
Fig. 55 Mexico market estimates and forecasts, 2018 - 2030
Fig. 56 Argentina market estimates and forecasts, 2018 - 2030
Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030
Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
Fig. 60 UAE market estimates and forecasts, 2018 - 2030
Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030

★調査レポート[世界のファーマコゲノミクス技術市場(2023-2030):治療領域別、技術別(PCR、インサイチュハイブリダイゼーション、免疫組織化学、シークエンシング、その他)、地域別] (コード:GRV23NOV180)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のファーマコゲノミクス技術市場(2023-2030):治療領域別、技術別(PCR、インサイチュハイブリダイゼーション、免疫組織化学、シークエンシング、その他)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆